Rosuvastatin: A highly effective new HMG-CoA reductase inhibitor

Cardiovascular Drug Reviews

Volumn 20, Issue 4, 2002, Pages 303-328

  Olsson, Anders G ^a   McTaggart, Fergus ^b   Raza, Ali ^b  

^a LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

^b ASTRAZENECA   (United Kingdom)

Author keywords

Atherosclerosis; Cholesterol; HMG CoA reductase inhibitors; Hypercholesterolemia; Rosuvastatin

Indexed keywords

APOLIPOPROTEIN B; ATORVASTATIN; CHOLESTEROL; COLESTYRAMINE; CYTOCHROME P450 2C9; CYTOCHROME P450 3A4; CYTOCHROME P450 INHIBITOR; DIGOXIN; ERYTHROMYCIN; FENOFIBRATE; FLUCONAZOLE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ITRACONAZOLE; KETOCONAZOLE; LIPID; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; STATINE DERIVATIVE; TRIACYLGLYCEROL;

ABDOMINAL PAIN; ATHEROGENESIS; ATHEROSCLEROSIS; BACKACHE; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DEATH; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFICACY; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG TOLERABILITY; DRUG UPTAKE; DRUG WITHDRAWAL; DYSLIPIDEMIA; FLU LIKE SYNDROME; HEADACHE; HUMAN; HYDROPHILICITY; HYPERCHOLESTEROLEMIA; LIPID BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; METABOLIC DISORDER; MORBIDITY; MORTALITY; MYALGIA; MYOPATHY; NAUSEA; NONHUMAN; PAIN; PHARYNGITIS; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0036963678     PISSN: 08975957     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1527-3466.2002.tb00099.x     Document Type: Review

References (67)

1. Andrews TC, Ballantyne CM, Hsia JA, Kramer JH. Achieving and maintaining National Cholesterol Education Program low-density lipoprotein cholesterol goals with five statins. Am J Med 2001;111:185-191.
2. Ballantyne C, Miller E, Chitra R. Rosuvastatin alone produces similar lipid benefits compared with rosuvastatin plus cholestyramine in patients with primary hypercholesterolemia. Int J Clin Pract 2002;124(Suppl):13.
3. Barter P, Shepherd J, Brown WV, Bays H, Southworth H, Strutt K. Rosuvastatin significantly improves lipid parameters and ability to achieve low-density lipoprotein cholesterol goals compared with pravastatin. J Am Coll Cardiol 2002;39(Suppl B):142B.
4. Brown CDA, Windass A, Bleasby K, Lauffart B. Rosuvastatin is a high affinity substrate of hepatic organic anion transporter OATP-C. Atherosclerosis 2001;Suppl 2:88.
5. Brown WV, Bays HE, Hassman DR. Efficacy and safety of rosuvastatin compared with pravastatin and simvastatin in patients with hypercholesterolemia: A randomized, double-blind, 52-week trial. Am Heart J 2002; in press.
6. Brown WV, Chitra RR, Zedler BK, Bays HE, Hassman HA. Long-term efficacy and safety of rosuvastatin: Results of a 52-week comparator-controlled trial versus pravastatin and simvastatin. Eur Heart J 2001;22(Suppl):270.
7. Brown WV, McKenney JM, Zedler BK, et al. A 52-week trial of rosuvastatin versus pravastatin and simvastatin in patients with primary hypercholesterolemia. Int J Clin Pract 2002;124(Suppl): 12.
8. Buckett L, Ballard P, Davidson R, et al. Selectivity of ZD4522 for inhibition of cholesterol synthesis in hepatic versus non-hepatic cells. Atherosclerosis 2000;151:41.
9. Capuzzi DM, Morgan JM, Weiss R, Chitra RR, Cressman MD, Hutchinson HG. Effects of rosuvastatin alone and combined with extended-release niacin on apo B- and apo A-containing lipoproteins and triglycerides in atherogenic dyslipidemia. Atherosclerosis Suppl 2002;3:82.
10. Caslake MJ, Stewart G, Day S, et al. Rosuvastatin normalises atherogenic levels of apo B-containing lipoprotein subfractions. Int J Clin Pract 2002;124(Suppl):8.
11. Chapman MJ, McTaggart F. Optimizing the pharmacology of statins: Characteristics of rosuvastatin. Atherosclerosis Suppl 2002;2:33-37.
12. Cooper KJ, Martin PD, Dane AL, Warwick MJ, Schneck DW, Cantarini M. Fluconazole has no clinically relevant effect on the pharmacokinetics of rosuvastatin. Pharmacol Toxicol 2001;89(Suppl 1):75.
13. Cooper KJ, Martin PD, Dane AL, Warwick MJ, Schneck DW. Lack of effect of ketoconazole on the pharmacokinetics of rosuvastatin. Br J Clin Pharmacol 2002; in press.
14. Cooper KJ, Martin PD, Dane AL, Warwick MJ, Schneck DW, Nwose OM. Erythromycin has no clinically relevant effect on the pharmacokinetics of rosuvastatin. Eur J Clin Pharmacol 2002; in press.
15. Crouse JR, Grobbee DE, O'Leary DH, et al. Measuring effects on intima media thickness: An evaluation of rosuvastatin - the METEOR study. Atherosclerosis Suppl 2002;3:94.
16. Davidson M, Ma P, Stein EA, Gotto AM Jr, Raza A, Chitra R, Hutchinson HG. Comparison of effects on low-density lipoprotein cholesterol and high-density lipoprotein cholesterol with rosuvastatin versus atorvastatin in patients with type IIa or lIb hypercholesterolemia. Am J Cardiol 2002;89:268-275.
17. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. Results of AFCAPS/TexCAPS. JAMA 1998;279:1616-1622.
18. Durrington P, Hamann A, Tuomilehto J, Smith K, Kallend D. Rosuvastatin alone and in combination with fenofibrate in hyperlipidaemic patients with type 2 diabetes. Diabetologia 2001;44(Suppl 1):A165.
19. Durrington PN, Tuomilehto J, Hamann A, Southworth H, Pears J, Kallend D. Effects of rosuvastatin alone and in combination with fenofibrate on lipid subfractions in patients with type 2 diabetes: Results at 24 weeks. Circulation 2001;104(Suppl II):II-177.
20. EUROASPIRE I and II Group. Clinical reality of coronary prevention guidelines: A comparison of EUROASPIRE I and II in nine countries. Lancet 2001;357:995-1001.
21. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486-2497. Full report available at www.nhlbi.nhi.gov.
22. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA 1993;269:3015-3023.
23. Hamilton-Craig I, Schaefer E, Farnier M, Koren M, Southworth H, Pears J. Rosuvastatin produces significantly greater reductions in low-density lipoprotein cholesterol and more patients achieve treatment goals compared with simvastatin. J Am Coll Cardiol 2002;39(Suppl B):146B.
24. Holdgate GA, Ward WHJ, Davidson M, Thornton M, March R, McTaggart F. Kinetics of inhibition of HMG-CoA reductase by a new statin, rosuvastatin. Atherosclerosis 2001;2(Suppl):90.
25. Hunninghake DB, Chitra RR, Simonson SG, Schneck DW. Effects of rosuvastatin on serum lipids and lipid subfractions in patients with hypertriglyceridemia. Int J Clin Pract 2002;124(Suppl):10.
26. Hunninghake DB, Chitra RR, Simonson SG, Schneck DW. Rosuvastatin markedly improved the atherogenic profile in hypertriglyceridaemic patients. Eur Heart J 2001;22(Suppl):270.
27. Istad H, Ose L, Stender S, Southworth H, Pears J. Achievement of the Joint European Societies LDL-cholesterol goal by hypercholesterolaemic patients receiving rosuvastatin or atorvastatin. Atherosclerosis Suppl 2002;3:130.
28. Istvan ES, Deisenhofer J. Structural mechanism for statin inhibition of HMG-CoA reductase. Science 2001;292:1160-1164.
29. Jones P, Kafonek S, Laurora I, et al. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES Study). Am J Cardiol 1998;81:582-587.
30. Jones SP, Gibson MF, Rimmer DM 3rd, Gibson TM, Sharp BR, Lefer DJ. Direct vascular and cardioprotective effects of rosuvastatin, a new HMG-CoA reductase inhibitor. J Am Coll Cardiol 2002;40:1172-1178.
31. Knopp RH, Ballantyne CM, McPherson R, Chitra RR, Schneck DW, Simonson SG. Comparing rosuvastatin and atorvastatin across their dose ranges in patients with hypercholesterolemia. Eur Heart J 2002;23(Suppl):19.
32. Laufs U, Gertz K, Dimagl U, Bohm M, Nickenig G, Endres M. Rosuvastatin, a new HMG-CoA reductase inhibitor, upregulates endothelial nitric oxide synthase and protects from ischemic stroke in mice. Brain Res 2002;942:23-30.
33. Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998;339:1349-1357.
34. Marais D, Raal F, Stein E, et al. Effect of rosuvastatin on LDL -cholesterol, mevalonic acid and other lipid measurements in patients with homozygous familial hypercholesterolaemia. Atherosclerosis Suppl 2002;3:159.
35. Martin PD, Cooper KW, Dane AL, Warwick MJ, Nwose OM, Cantarini M. Itraconazole produces modest increases in rosuvastatin plasma concentrations. Pharmacol Toxicol 2001;89(Suppl 1):77-78.
36. Martin PD, Dane AL, Nwose D, Schneck DW, Warwick MJ. No effects of age or gender on the pharmacokinetics of rosuvastatin - a new HMG-CoA reductase inhibitor. J Clin Pharmacol 2002; in press.
37. Martin PD, Dane AL, Schneck DW, Warwick MJ. Disposition of new HMG-CoA reductase inhibitor ZD4522 following dosing in healthy subjects. J Clin Pharmacol 2000;40:1056.
38. Martin PD, Kemp J, Dane AL, Warwick MJ, Schneck DW. No effect of rosuvastatin on the pharmacokinetics of digoxin in healthy volunteers. J Clin Pharmacol 2002; in press.
39. Martin PD, Mitchell PD, Schneck DW. Pharmacodynamic effects and pharmacokinetics of a new HMG-CoA reductase inhibitor, rosuvastatin, after morning or evening administration in healthy subjects. Br J Clin Pharmacol 2002; in press.
40. McCormick AD, McKillop D, Butters CJ, et al. ZD4522 - an HMG-CoA reductase inhibitor free of metabolically mediated drug interactions: Metabolic studies in human in vitro systems. J Clin Pharmacol 2000;40:1055.
41. McTaggart F, Buckett L, Davidson R, et al. Preclinical and clinical pharmacology of rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. Am J Cardiol 2001;87(Suppl):28B-32B.
42. Morgan JM, Cressman MD, Hutchinson HG, Capuzzi DM. Beneficial effects of combination therapy with rosuvastatin and extended-release niacin in patients with a mixed dyslipidemia. Int J Clin Pract 2002;124(Suppl):14.
43. MRC/BHF Heart Protection Study: Preliminary results. Conference report. Int J Clin Pract 2002;56:53-56.
44. Nezasa K, Higaki K, Hasegawa H, et al. Uptake of HMG-CoA reductase inhibitor ZD4522 into hepatocytes and distribution into liver and other tissues of the rat. Atherosclerosis 2000;151:39.
45. Olsson AG, Istad H, Luurila O. Effects of rosuvastatin and atorvastatin compared over 52 weeks of treatment in hypercholesterolemic patients. Am Heart J 2002; in press.
46. Olsson AG, Pears J, McKellar J, Mizan J, Raza A. Effect of rosuvastatin on low-density lipoprotein cholesterol in patients with hypercholesterolemia. Am J Cardiol 2001;88:504-508.
47. Olsson AG, Southworth H, Wilpshaar JW. A 52-week trial of rosuvastatin versus atorvastatin in patients with primary hypercholesterolemia. Int J Clin Pract 2002;124(Suppl):11.
48. Olsson AG, Southworth H, Wilpshaar JW. Long-term efficacy and safety of rosuvastatin: Results of a 52-week comparator-controlled trial versus atorvastatin. Eur Heart J 2001;22(Suppl):253.
49. Paoletti R, Fahmy M, Mahla G, Mizan J, Southworth H. Rosuvastatin demonstrates greater reduction of low-density lipoprotein cholesterol compared with pravastatin and simvastatin in hypercholesterolaemic patients: A randomized, double-blind study. J Cardiovasc Risk 2001;8:383-390.
50. Paoletti R, Pisciotta L, Southworth H, Carbarns I. Achievement of the Joint European Societies LDL-cholesterol goal by hypercholesterolaemic patients receiving rosuvastatin, pravastatin or simvastatin. Atherosclerosis Suppl 2002;3:180.
51. Pearson TA, Laurora I, Chu H, et al. The Lipid Treatment Assessment Project (L-TAP): A multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med 2000;160:459-467.
52. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996;335:1001-1009.
53. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-1389.
54. Second Joint Task Force. Prevention of coronary heart disease in clinical practice. Recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention. Eur Heart J 1998;19: 1434-1503.
55. Shepherd J, Carbams I, Harris S, Caplan R, Pears J. Safety of rosuvastatin in patients developing LDL-C <80 mg/dL and <50 mg/dL in clinical trials. Atherosclerosis Suppl 2002;3:205.
56. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995;333:1301-1307.
57. Shepherd J, Hunninghake D, Harris S, Hutchinson H, Pears J. A review of the safety profile of rosuvastatin in an international phase II/III clinical trial programme. Int J Clin Pract 2002;124(Suppl):15.
58. Simonson SG, Martin PD, Mitchell PD, Schneck DW. Pharmacokinetics and pharmacodynamics of rosuvastatin in hepatically impaired subjects. Clin Pharmacol Ther 2001;69:86.
59. Stalker TJ, Lefer AM, Scalia R. A new HMG-CoA reductase inhibitor, rosuvastatin, exerts anti-inflammatory effects on the microvascular endothelium: The role of mevalonic acid. Br J Pharmacol 2001;133:406-412.
60. Stein EA, Strutt KL, Miller E, Southworth H. Effect of rosuvastatin on high density lipoprotein cholesterol and apolipoprotein A-I in patients with heterozygous familial hypercholesterolemia. Int J Clin Pract 2002; 124(Suppl):9.
61. Stein E, Strutt KL, Miller E, Southworth H. Rosuvastatin (20, 40 and 80 mg) reduces LDL-C, raises HDL-C and achieves treatment goals more effectively than atorvastatin (20, 40 and 80 mg) in patients with heterozygous familial hypercholesterolaemia. Atherosclerosis 2001;Suppl 2:90.
62. Stein E, Strutt KL, Miller E, Southworth H. ZD4522 is superior to atorvastatin in the treatment of patients with heterozygous familial hypercholesterolemia. J Am Coll Cardiol 2001;37(Suppl A):292A.
63. Vale MJ, Jelinek MV, Best JD. How many patients with coronary heart disease are not achieving their risk-factor targets? Experience in Victoria 1996-1998 versus 1999-2000. Med J Aust 2002;176:211-215.
64. Warwick MJ, Dane AL, Raza A, Schneck DW. Single- and multiple-dose pharmacokinetics and safety of the new HMG-CoA reductase inhibitor ZD4522. Atherosclerosis 2000;151:39.
65. Werner N, Priller J, Laufs U, et al. Bone marrow-derived progenitor cells modulate vascular reendothelialization and neointimal formation. Effect of 3-hydroxy-3-methylglutaryl coenzyme inhibition. Arterioscler Thromb Vasc Biol 2002;22:1567-1572.
66. Wiklund O, Davidson M, Chitra R, Hutchinson H, Raza A. Rosuvastatin is more effective than atorvastatin in modifying lipid profiles and achieving National Cholesterol Education Program Adult Treatment Panel III LDL-cholesterol goals. Atherosclerosis Suppl 2002;3:237.
67. Zedler B, Davidson M, Ose L, Chitra R, Carbarns I. Rosuvastatin improves ability to achieve low-density lipoprotein cholesterol goals compared with atorvastatin, pravastatin, and simvastatin. J Am Coll Cardiol 2002;39(Suppl B):143B.